Systemic Scleroderma Clinical Trial
Official title:
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA IN THE CONTEXT OF THE DEVELOPMENT OF AN INNOVATIVE CELLULAR THERAPY FOR THE TREATMENT OF FUNCTIONAL HANDICAP OF THE HAND
The overall objective is to propose a comprehensive analysis of the biological properties of
the stromal vascular fraction evaluated in the SCLERADEC 2 clinical trial (n = 15 available)
and preserved in the biological collection, compared to healthy donors (n = 10). This
characterization will focus on the exploration of the phenotypic and functional
characteristics of the main cellular subpopulations present in the stromal vascular fraction
of scleroderma patients likely to be associated with a better regenerative vascular or
anti-fibrotic activity of the cell therapy product.
The main objective will be to validate whether the supposed mechanism of action of this
innovative therapy, in relation to the representativity of the endothelial progenitors,
carrying the vascular regeneration activity, is preserved in the sclerodermic context.
A total of 30 subjects (20 systemic Scleroderma patients and 10 healthy donors) will be
included.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00377455 -
Placebo Controlled Trial of Bosentan in Scleroderma Patients
|
Phase 2 | |
| Completed |
NCT00278525 -
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
|
Phase 2 | |
| Completed |
NCT00318188 -
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
|
N/A | |
| Completed |
NCT03575156 -
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
|
N/A | |
| Active, not recruiting |
NCT01413100 -
Scleroderma Treatment With Autologous Transplant (STAT) Study
|
Phase 2 | |
| Completed |
NCT00622895 -
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03816189 -
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
|
||
| Completed |
NCT01295736 -
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
|
Phase 3 | |
| Completed |
NCT02213705 -
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03508375 -
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
|
N/A | |
| Active, not recruiting |
NCT01309997 -
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Completed |
NCT00697736 -
Cardiac Repercussion of Systemic Sclerodermias
|
N/A | |
| Completed |
NCT02349009 -
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT00318175 -
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT03262922 -
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
|
||
| Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
| Recruiting |
NCT04380831 -
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
|
Early Phase 1 | |
| Terminated |
NCT00628797 -
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05672992 -
Longitudinal Spatial Frequency Domain Imaging Study
|
N/A | |
| Recruiting |
NCT05726630 -
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
|
Phase 3 |